Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

CABOMETYX DIN 02480840

Status: Marketed
Holder: IPSEN BIOPHARMACEUTICALS CANADA INC
Molecule: CABOZANTINIB (CABOZANTINIB MALATE)
Available to quote

Health Canada record

Active ingredient(s)CABOZANTINIB (CABOZANTINIB MALATE) 60 MG
Dosage formTablet
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCL01EX07 CABOZANTINIB
Original market date10-Oct-2018
Current status date10-Oct-2018
SourceHealth Canada DPD

Establishment licence of the holder

Ipsen Biopharmaceuticals Canada Inc — licence 102222, currently licensed, last inspection rating C (2024-05-06).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing CABOZANTINIB (CABOZANTINIB MALATE)

DINProductCompanyFormStrengthStatus
02480824CABOMETYXIPSEN BIOPHARMACEUTICALS CANADA INCTabletCABOZANTINIB (CABOZANTINIB MALATE) 20 MGMarketed
02480832CABOMETYXIPSEN BIOPHARMACEUTICALS CANADA INCTabletCABOZANTINIB (CABOZANTINIB MALATE) 40 MGMarketed

Notices of Compliance

NOCDateSubmissionReason
213092018-09-14New Drug Submission (NDS)
Request a quote for CABOMETYX

How to read a Canadian DIN record